Novel smoothened antagonists as anti‐neoplastic agents for the treatment of osteosarcoma
- 15 January 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (6) , 4961-4971
Abstract
Osteosarcoma (OS) is an ultra‐rare highly malignant tumor of the skeletal system affecting mainly children and young adults and it is characterized by an extremely aggressive clinical course. OS patients are currently treated with chemotherapy and complete surgical resection of cancer tissue. However, resistance to chemotherapy and the recurrence of disease, as pulmonary metastasis, remain the two greatest challenges in the management, and treatment of this tumor. For these reasons, it is of primary interest to find alternative therapeutic strategies for OS. Dysregulated Hedgehog signalling is involved in the development of various types of cancers including OS. It has also been implicated in tumor/stromal interaction and cancer stem cell biology, and therefore presents a novel therapeutic strategy for cancer treatment. In our work, we tested the activity of five potent Smoothened (SMO) inhibitors, four acylguanidine and one acylthiourea derivatives, against an OS cell line. We found that almost all our compounds were able to inhibit OS cells proliferation and to reduce Gli1 protein levels. Our results also indicated that SMO inhibition in OS cells by such compounds, induces apoptosis with a nanomolar potency. These findings suggest that inactivation of SMO may be a useful approach to the treatment of patients with OS.Keywords
Funding Information
- Fondazione Telethon (GGP10058)
- Istituto Toscano Tumori (2008)
This publication has 41 references indexed in Scilit:
- A Simple High-Content Cell Cycle Assay Reveals Frequent Discrepancies between Cell Number and ATP and MTS Proliferation AssaysPLOS ONE, 2013
- Targeting hedgehog‐GLI‐2 pathway in osteosarcomaJournal of Orthopaedic Research, 2012
- Post‐genomics of bone metabolic dysfunctions and neoplasiasProteomics, 2012
- The Molecular Pathogenesis of Osteosarcoma: A ReviewSarcoma, 2011
- Smoothened as a new therapeutic target for human osteosarcomaMolecular Cancer, 2010
- Activation of the hedgehog-signaling pathway in human cancer and the clinical implicationsOncogene, 2009
- Hedgehog: functions and mechanismsGenes & Development, 2008
- Therapy for OsteosarcomaPediatric Drugs, 2008
- The Gli code: an information nexus regulating cell fate, stemness and cancerTrends in Cell Biology, 2007
- Constitutive Hedgehog Signaling in Chondrosarcoma Up-Regulates Tumor Cell ProliferationThe American Journal of Pathology, 2006